---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-029239"
form_type: "8-K"
ticker: "ORIC"
cik: "0001796280"
company_name: "Oric Pharmaceuticals, Inc."
filed_at: "2024-03-11T23:59:59+00:00"
generated_at: "2026-06-04T23:57:08.215336+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# ORIC Pharma Q4 2023: R&D expenses up to $24.5M; cash $235M; pipeline progress on ORIC-944/114

## Summary
- Q4 2023 R&D expenses $24.5M (up $8.2M YoY); G&A $6.9M; cash and investments $235M at Dec 31, 2023.
- Two private placements raised $85M (June 2023) and $125M (Jan 2024); pro forma cash $351.8M at Jan 31, 2024, funding into late 2026.
- Initial Phase 1b data for ORIC-114 (EGFR/HER2) and ORIC-944 (PRC2) show best-in-class potential; dose expansion for ORIC-114 in mutated NSCLC expected H1 2024.
- ORIC-533 (CD73 inhibitor) Phase 1b dose escalation completed Q1 2024; company plans strategic partnership for combination studies.
- ORIC-944 combination study with AR inhibitor to start H1 2024; program update mid-2024. Discovery includes PLK4 inhibitor ORIC-613 advancing.

## SEC filing metadata
- accession: 0000950170-24-029239
- form_type: 8-K
- ticker: ORIC
- cik: 0001796280
- company_name: Oric Pharmaceuticals, Inc.
- filed_at: 2024-03-11T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1796280/000095017024029239/0000950170-24-029239-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1796280/000095017024029239/oric-20240311.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-029239
- JSON: https://secwatch.observer/filing/0000950170-24-029239.json
- Plain text: https://secwatch.observer/filing/0000950170-24-029239.txt

## Key facts
- Earnings Releases
  Oric Pharmaceuticals, Inc. reported financial results for the fourth quarter and full year ended December 31, 2023.
  - Period: the fourth quarter and full year ended December 31, 2023
  - Result: reported results
  source text: On March 11, 2024, ORIC Pharmaceuticals, Inc. issued a press release announcing its financial results for the fourth quarter and full year ended December 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1796280/000095017024029239/0000950170-24-029239-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.